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There is ample evidence to support the proposal that most, if not all, tumors possess 
tumor-specific antigens and are immunogenic to varying degrees. This proposal rests on 
two main lines of evidence. First, that a state of specific immunity to growth of a tumor 
cell challenge can be generated in a host pre-exposed to various immunizing regimens 
with tumor cells (reviewed in reference  1).  Second,  that a  host bearing a  progressive 
autochthonous or syngeneic tumor burden can, nevertheless, acquire a powerful mecha- 
nism of systemic immunity capable of eradicating a lethal challenge inoculum of cells of 
the  same  tumor  line.  This  second  type  of immunity  is  referred  to  as  concomitant 
immunity (2), and there is convincing evidence (3-5) that it is T-cell mediated. That this 
state of immunity represents a  relatively common response to growing neoplasms is 
indicated  by the  numerous  demonstrations  (1,  6)  of the  presence  in  tumor-bearing 
humans and animals of lymphocytes that are specifically cytotoxic for tumor cells in 
vitro. 
It was recently shown (5) that the generation of T-cell-mediated concomitant immunity 
to murine fibrosarcomas is associated with the concordant generation of an activated 
macrophage system. This was evidenced by a limited capacity of concomitantly immune 
mice for inhibiting the growth of antigenically unrelated tumors, but more convincingly 
by a striking enhancement in their capacity for destroying lethal challenge inocula of the 
bacterial parasite, Listeria monocytogenes. It was concluded, therefore, that the response 
to the tumor involved the generation of a population of sensitized T cells that mediated 
the activation of macrophages. In spite of the presence of  these effector cells, however, the 
host nevertheless remained incapable of ridding itself of its primary tumor burden. 
It is considered by many that this paradox can be satisfactorily explained on the basis 
of the action of antigen and antibody-dependent blocking factors (7, 8), which have been 
shown to be present in the serum of tumor bearers, and to be capable of neutralizing the 
cytotoxicity of sensitized lymphocytes for tumor cells in vitro.  Although the evidence 
supporting a role for blocking factors is persuasive, it is well to realize that it is based 
almost exclusively upon  studies  that have been  conducted  in  vitro.  In fact,  there  is 
evidence (9) that could be interpreted as casting doubt on a role for blocking factors in 
vivo.  The possibility remains,  therefore,  that other mechanisms may also operate to 
protect a progressive tumor from the anti-tumor immunity it evokes; mechanisms that 
would  also need  to  account  for the  ability  of the  tumor to avoid destruction  by the 
demonstrated (10-12)  tumoricidal powers of activated macrophages. 
Indeed, that tumors may possess mechanisms that subvert the anti-tumor activity of 
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macrophages was recently revealed by the demonstration (13) that implantation of small 
numbers of murine neoplastic cells resulted in a  rapid systemic suppression of macro- 
phage  function.  This  was  measured  as  a  strikingly reduced  capacity of the  host for 
expressing  macrophage-mediated resistance  to  microbial infection,  and  as  a  state  of 
suppressed native resistance to growth of a tumor cell implant. It was further shown (14) 
that the suppression of macrophage function was caused by a soluble factor that persisted 
in circulation long after the tumor-bearing host had counteracted its effects systemically 
by generating concomitant immunity and an activated macrophage system. It seemed 
reasonable to propose, therefore, that the factor was produced by the tumor itself, and 
that  the  host  remained  incapable of rejecting its primary tumor  because  it failed to 
counteract the  suppressive  effects of much  higher concentrations  of the  factor in the 
tumor. The additional possibility arises, moreover, that besides suppressing the function 
of macrophages, the presence of this factor in the tumor might also be responsible for 
suppressing the expression of specific anti-tumor immunity by sensitized T  cells. 
The studies presented  in this paper were designed to examine  the hypothesis 
that  an  established  primary  tumor  presents  an  environment  that  is not  only 
antagonistic to the expression of anti-tumor  immunity,  but is also antagonistic 
to the  expression of host  defenses  in  general.  They  will show  that  a  striking 
similarity  exists between  the capacity of a  tumor-bearing  animal  to express T- 
cell-mediated concomitant  anti-tumor  immunity,  and its capacity to express T- 
cell-mediated  anti-bacterial  immunity,  in  that  while  both  can  be  efficiently 
expressed  systemically,  neither  can  be  fully  expressed  within  the  growing 
tumor. 
Materials and Methods 
Animals.  Parental A/J,  DBA/2J,  C57BL/6J,  and BALB/cJ mice were purchased from The 
Jackson Laboratory, Bar Harbor, Maine, and used to produce AB6F  1 (A/J x  C57BL/6).  CB6F1 
(BALB/c  ×  C57BL/6)~ and B6D2F~ (C57BL/6  x  DBA/2) hybrids. They were incorporated into 
experiments when they were 8-12 wk of age. 
Tumors.  The SA1 spindle cell sarcoma syngeneic in A/J, the Meth A fibrosarcoma syngeneic 
in  BALB/c,  and the  P815  mastocytoma syngeneic in  DBA/2  were  studied.  The  experiments 
reported here were performed using a single biofrozen stock of cells of each tumor harvested in 
ascites from the peritoneal cavities of large numbers of syngeneic mice. Cells of each tumor were 
harvested in heparinized phosphate-buffered saline (PBS), ~ pooled, washed in PBS, and resus- 
pended in MEM containing 20% fetal calf serum and 20% dimethyl sulfoxide. They were then 
biofrozen, and stored in liquid nitrogen until required. Before each experiment an aliquot was 
thawed, washed in PBS, and grown in the peritoneal cavity of an appropriate semisyngeneic host 
for 7 days. The cells were harvested and washed in PBS, examined for viability by trypan blue 
exclusion, and suspended at an  appropriate concentration in PBS for initiating experimental 
tumors either subcutaneously or intraperitoneally. 
Solid tumors were initiated by injecting tumor cells into the plantar surface of one of the hind 
foot pads in a vol of 0.05 ml with a 30 gauge needle. Enough tumor cells were implanted to give a 
palpable tumor that caused 1.0-1.8 mm dorsoventral foot pad swelling in 6 days. This required 105 
SA1 cells, and 2  ×  106 cells each for the Meth A and mastocytoma. Growth of the tumors was 
monitored against time by measuring further increases in the dorsoventral thickness of the foot 
with dial calipers. Ascites tumors in all cases were initiated by infusing 5  ×  10  ~ cells into the 
peritoneal cavity. In all cases, experiments were performed with animals bearing 6-day tumors. 
Bacteria.  A log phase culture ofL. monocytogenes  (strain EGD) was grown in Trypticase-soy 
broth, and stored in aliquots at -70°C. For each experiment an aliquot was quickly thawed at 37°C 
and diluted in a standard fashion in 0.9% sodium chloride for intratumor, intravenous, intraperi- 
toneal, or subcutaneous inoculation. Growth of the organism was followed against time in the 
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liver, tumor-bearing foot,  normal foot, and in the draining popliteal lymph node.  This required 
plating 10-fold serial dilutions of tissue homogenates on Trypticase-soy agar.  Livers and lymph 
nodes were homogenized in a  glass tube with a  loose  fitting Teflon pestle; tumor-bearing and 
normal feet were homogenized with a high speed VirTis tissue grinder (VirTis Co., Inc., Gardiner, 
N. Y.). Preliminary experiments showed that it was possible by this method to recover all bacteria 
from normal and tumor-bearing foot pads 30 min after inoculation. To follow the growth of  Listeria 
in the peritoneal cavity, the peritoneal contents were harvested in 2 ml of heparinized PBS and 
subjected for 5 s to sonication to release intracellular bacteria. In some experiments the number of 
cell-associated bacteria was distinguished from the number present extracellularly by centrifug- 
ing the peritoneal washings at 200 g  for 10 min and enumerating the bacteria in the washed 
cell button and in the supernate. 
Tumor-Induced Anti-Bacterial Resistance.  Systemic resistance to Listeria  was expressed as 
the log~ resistance index as described previously (5). It was calculated as the difference between 
the 48 h growth of a standard 2 x 103 intravenousListeria  inoculum in the livers of tumor-bearing 
mice and its 48°h growth in the livers of control mice. 
Irradiation.  Whole-body  gamma-irradiation was performed in a  cesium-137  irradiator at a 
midphantom dose rate of 35.5 rads/min. 
Results 
Suppressed Anti-Bacterial Resistance  in Progressive Tumors.  The experi- 
ments reported in this section were designed to test the prediction that the 
conditions within a primary tumor which inhibit the expression of concomitant 
anti-tumor immunity would be reflected by a failure of the host to express anti- 
bacterial resistance in the same site. This was investigated by comparing the 
growth of a sublethal number of Listeria inoculated into an established 6-day 
foot pad tumor with the growth of the same number inoculated into the contra- 
lateral foot pad. It can be seen in Fig. 1 that growth of the organism in foot pads 
carrying the SA1  sarcoma, P815 mastocytoma, or Meth A  fibrosarcoma pro- 
gressed log linearly for 2 days, and then either continued at a slower rate, or 
plateaued. In contrast, Listeria was efficiently eliminated from the tumor-free 
contralateral foot pads at the same rate as from the foot pads of tumor-free 
control mice. 
Whereas Fig.  1 refers to results obtained with semisyngeneic mice, Fig.  2 
serves to show that the same results were obtained with syngeneic mice. Thus, 
it  can be  seen again  that  while A/J mice carrying the  SA1  sarcoma were 
incapable of eliminating Listeria from their tumor-bearing foot pacls they easily 
eliminated the organism from their contralateral foot pads. 
Additional evidence to support the conclusion that tumor-bearing mice are 
capable of eliminating Listeria from any site except the tumor is presented in 
Fig. 3. This figure contrasts the growth of  bacteria in the tumor with the growth 
of those organisms that were seeded from the tumor into the draining lymph 
node and the liver. It can be seen that while large numbers of bacteria persisted 
in the tumor, they were progressively eliminated during the same time from the 
lymph node and liver. From a wealth of studies (reviewed in reference 15) there 
is little doubt, therefore, that despite the persistence of bacteria in the tumor, 
the host beth acquired and expressed anti-bacterial immunity systemically. 
It can be seen from the results in Fig. 4, furthermore, that destruction of  those 
bacteria that found their way from the tumor to the lymph node and liver 
probably cannot be attributed exclusively to the action of specific anti-bacterial 
immunity. That an additional mechanism of resistance must have contributed GEORGE  L.  SPITALNY AND ROBERT J.  NORTH  1267 
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FIG.  2.  Same result as Fig. 1 except that experiment was performed with SA1 in syngeneic 
mice. Means of five mice __ SE. 
to the systemic destruction of microorganisms is evidenced by the faster rate of 
bacterial destruction in the lymph nodes and livers of tumor-bearing mice than 
in the livers and lymph nodes of  tumor-free controls. This occurred, moreover, in 
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Fro. 3.  Additional evidence that  the  tumor-bearing host  can  efficiently  eliminate bacteria 
from any place  but  its  tumor. Compared is  the  growth of  Listeria in  a 6 day SAt, Meth A, or 
mastocytoma foot  pad tumor, with its growth in the draining lymph node and the liver. 
The organism was seeded  into  the  lymph node and  liver  from  the  tumor. Means of  five  mice 
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Evidence that that tumor-bearing host has a greater capacity than a tumor-free 
host for inactivating Listeria systemically. Listeria was inoculated into the tumor-bearing 
foot pad of SA1 tumor bearers, and into the foot pad of tumor-free controls, and the growth 
of bacteria that were seeded into the lymph nodes and livers followed.  Although approxi- 
mately the same number of bacteria were initially seeded into the nodes and livers of both 
groups of mice, bacteria were more rapidly eliminated from the nodes and livers of tumor 
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Fro.  5.  Evidence that the response to the tumor itself results in the generation of anti- 
Listeria resistance. The right hind foot pads of mice were implanted with 5 x  105 SA1 cells 
and their capacity to resist an intravenous  (2  x  103) challenge inoculum of Listeria  was 
compared with  this  capacity in  control  mice on the days of tumor  growth  (line graph) 
indicated.  Shown are differences (log,o resistance, bar graph) between the 48-h growth of 
the organism in the livers of tumor bearers  and controls.  The tumor bearers developed 
strikingly increased anti-bacterial resistance after day 6 of tumor growth.  Means of five 
mice. 
the large bacterial population in the tumor. 
Indeed, it is known from previous publications (5, 13) that progressive growth 
of the tumors employed in this study, results, via the generation of concomitant 
immunity, in the activation of macrophages, and hence in an enhanced  capacity 
of the host for rapidly inactivating an intravenous Listeria challenge inoculum. 
Direct evidence for this point is illustrated in Fig. 5 which measures changes 
against time of tumor growth, in the capacity of macrophages in the livers of 
tumor bearers to resist a  standard 2  ×  10  3 Listeria  inoculum given intrave- 
nously. It can be seen that the host's response to the tumor itself resulted in an 
enhanced capacity to nonspecifically destroy the bacterial challenge. By day 10 
of tumor growth, for instance, tumor bearers showed two logs less growth of 
bacteria in their livers than controls. Since all of the foregoing results were 
based on the use of 6-day tumors, it is obvious that they were obtained with mice 
that had already begun to acquire an appreciable level of tumor-induced anti- 
microbial resistance based on the response to the tumor itself. 
Effect  of Bacteria  on  Tumor  Growth.  Fig.  6  compares the  growth of a 
Listeria-infected foot pad tumor with the growth of a noninfected tumor. It can 
be seen that a large number of replicating bacteria inhibited progressive tumor 
growth. It was found, however, that inhibition of tumor growth was temporary, 
in that it always eventually resumed in the case of the SA1 and mastocytoma, 
and resumed in most cases with the Meth A (results not shown). It is significant, 
moreover, that  on  those  very few occasions when infected Meth A  tumors 
completely  regressed, the bacteria were also completely  eliminated from the foot 1270  SUBVERSION  OF HOST DEFENSE  MECHANISMS  BY MALIGNANT TUMORS 
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FIG.  6.  Intratumor inoculation of Listeria resulted in suppression of growth of all three 
foot pad tumors.  However,  in  all cases  with the SA1  and mastocytoma  tumors,  and in 
practically all cases with the Meth A, tumor growth resumed at a normal rate by the 12th 
and 14th day (not shown). Means of five mice -+ SE. 
pad.  The apparent initial increase in tumor growth that followed intratumor 
inoculation of Listeria in the mastocytoma and Meth A as shown in Fig. 6, was 
probably  the  result  of an  initial  inflammatory response  to  the  presence of 
bacteria. 
Evidence  that  Anti-Bacterial  Resistance  is  Partially  Expressed  in  Tu- 
mors.  It was demonstrated by the foregoing sections that a tumor-bearing host 
is incapable of completely eliminating  Listeria from its primary tumor. Instead, 
at a time when the host was eliminating microorganisms from nonmalignant 
tissues with its acquired anti-bacterial defenses, bacteria either continued to 
grow in the tumor at a slower rate or their growth plateaued. The onset of the 
reduced rate of bacterial growth indicates, however, that the expression of anti- 
bacterial resistance was not completely blocked in the tumor, otherwise bacte- 
rial growth would have continued log linearly. That anti-bacterial resistance 
was partially expressed is indicated by the results in Fig. 7, which measured the 
effect of lethal whole-body gamma irradiation on bacterial growth in the SA1 
sarcoma.  It  can  be  seen  that  whole-body irradiation  resulted  in  the  rapid 
resumption of log linear bacterial growth both in the tumor-bearing and the 
tumor-free  foot pads. It follows, therefore, that irradiation abolished a radiosen- 
sitive component of anti-bacterial resistance that was being partially expressed 
in the tumor. Needless to say, mice so treated quickly succumbed to an over- 
whelming systemic bacterial infection. 
An Ascites  Tumor  as  a  Site  of Suppressed  Anti-Bacterial Resistance.  It 
could be argued that bacteria persist in a solid tumor because the architecture of 
the tumor presents physical or mechanical barriers to the entry of host effector 
cells.  This  possibility  is  made unlikely, however,  in  view of the  results  of GEORGE L.  SPITALNY AND ROBERT J.  NORTH  1271 
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FIG.  7.  Evidence that anti-bacterial resistance is partially expressed within a progressive 
tumor. Whole-body gamma irradiation resulted in resumption of rapid bacterial multiplica- 
tion in the SAl-bearing and contralateral foot pads. This means that bacterial growth was 
being partially restricted in the tumor by a  radiosensitive anti-bacterial defense mecha- 
nism. Means of five mice _+ SE. Irrad., irradiated; r, rads. 
experiments presented in Fig.  8 which compared the growth of a  10  4 Listeria 
inoculum in the peritoneal cavities of animals bearing 6-day ascites tumors, 
with the growth of the same number inoculated into the peritoneal cavities of 
control mice. It can be seen that substantially more bacterial multiplication took 
place in the peritoneal cavities containing replicating cells of the SA1 sarcoma, 
mastocytoma, or Meth A  fibrosarcoma. In fact, unlike a  solid tumor where 
bacterial growth either slowed down or plateaued al~er 2 days, bacterial growth 
in  ascites tumors continued log linearly, and soon resulted in death from a 
fulminating systemic infection. Preliminary experiments suggest that this was 
not the result of a systemically suppressed state of anti-bacterial resistance, but 
was caused instead by the escape of massive and overwhelming numbers of 
bacteria from the peritoneal cavity into the circulation. 
The  Distribution  of Bacteria  in  the  Tumor.  It  could be  suggested that 
Listeria persists in a tumor because it is interiorized by tumor cells and thus 
made inaccessible to destruction by host effector cells. Indeed, Fig. 9 shows that 
when washings of infected ascites tumors were subjected to centrifugation, most 
bacteria were found to be associated with the cell button. An examination of  the 
location of bacteria in ascites tumors revealed, however, that this was not the 
result of their association with tumor cells. On the contrary, the stained smears 
revealed that bacteria were cell associated because they were inside macro- 
phages in very large numbers (Fig.  10). It was obvious, moreover, that most of 
the macrophages were so heavily parasitized that they were destined to die. 
Occasionally, polymorphonuclear leukocytes were also seen to be replete with 
bacteria. 1272  SUBVERSION  OF HOST DEFENSE  MECHANISMS  BY MALIGNANT TUMORS 
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Fro.  8.  Evidence that the host is incapable of expressing anti-bacterial resistance in an 
ascites tumor. Compared is the growth of a  10  4 inoculum of  Listeria in the peritoneal cavity 
of mice bearing 6-day peritoneal ascites tumors, with the growth of the same inoculum in 
the  peritoneal  cavities  of normal  mice.  Tumor-bearing  mice  rapidly  succumbed  to  an 
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Evidence that most bacteria in ascites tumors were associated with cells. Means of 
five mice. 
Histologic examination of a solid foot pad tumor injected with Listeria, on the 
other hand, revealed that bacteria were distributed throughout the necrotic core 
as well as in the encompassing ring of living tumor cells and stroma. Clusters of 
microorganisms  were seen in  apparent  association with  cells,  but it was not 
determined whether the cells involved were macrophages.  Electron microscopy 
is therefore being currently employed to identify the cell types involved. GEORGE  L.  SPITALNY  AND ROBERT J.  NORTH  1273 
FIG.  10.  Stained smear of a peritoneal SA1 ascites tumor showing the presence of Listeria 
inside macrophages, and its absence from the cytoplasm of tumor cells (x  1,025). 
Discussion 
The results presented in this paper show that mice bearing any one of three 
syngeneic murine tumors,  although capable  of systemically generating and 
expressing acquired T-cell-mediated immunity to the bacterial parasite L. mon- 
ocytogenes  are,  nevertheless, incapable  of expressing this  immunity within 
their primary tumors. It was demonstrated that whereas Listeria  inoculated 
into a normal foot pad grew for 2 days and was then progressively eliminated by 
acquired anti-microbial immunity, the same number of bacteria inoculated into 
the contralateral foot pad bearing a 6 day established tumor either continued to 
grow at a slower rate, or failed to be eliminated. This occurred, moreover, in 
spite of the fact that tumor-bearing mice actually displayed a  greater initial 
capacity for inactivating Listeria systemically  than did normal mice, because of 
the generation of activated macrophages in response to the tumor itself. It was 
shown in a previous publication from this laboratory, furthermore, (5) that this 
tumor-induced state of macrophage activation is a consequence of the genera- 
tion of T-cell-mediated concomitant anti-tumor immunity in response to pro- 
gressive tumor growth. 
It is well established that acquired immunity to L. monocytogenes is depend- 
ent on the generation of sensitized T  cells which mediate the  activation of 
macrophages that function to express immunity. That a macrophage system so 1274  SUBVERSION OF HOST DEFENSE MECHANISMS BY MALIGNANT TUMORS 
activated also gives the host the capacity to resist the growth of implanted 
syngeneic tumor cells is evidenced by the results of unpublished experiments in 
this laboratory which show that 6-day Listeria-infected mice can prevent the 
growth of threshold implants of tumor cells, as well as retard the growth of 
larger implants. There is little doubt that fully functional populations of media- 
tor T  cells and effector macrophages were generated in response to Listeria 
infection in tumor-bearing mice; otherwise, Listeria would not have been inacti- 
vated systemically. Direct evidence for this statement, moreover, will appear in 
a  forthcoming publication. It follows, therefore, that the reason why Listeria 
was not eliminated from the tumor was because the mediator and effector cells 
of anti-bacterial immunity were either prevented from entering the tumor in 
adequate numbers, or their functions were suppressed after they entered. 
Evidence that tumor cells secrete pharmacologically active molecules that 
suppress the function of macrophages and prevent their emigration into sites of 
tissue disturbance is rapidly accumulating. It was recently shown (13) in this 
laboratory, for instance, that subcutaneous implantation of cells of the same 
tumors employed in the present study, rapidly resulted in the liberation of a 
small molecular weight factor into the circulation which severely suppressed 
native and acquired macrophage-mediated resistance to bacterial infection. The 
effects of this factor, however, were eventually counteracted systemically by the 
generation of concomitant immunity and an activated macrophage system (14). 
However, because the serum of these mice continued to contain enough of the 
factor to suppress anti-bacterial  resistance in normal recipients, it was sug- 
gested that the source of this factor was the tumor itself, and that it was present 
there in suppressive concentrations. Whether the presence of such a factor was 
responsible for the failure of mice to express anti-bacterial resistance as reported 
here has yet to be determined. This appears a likely possibility, however, when 
considered in  conjunction with recent publications which show that murine 
tumor cells contain a  small molecular weight factor that both inhibits macro- 
phage chemotaxis in vitro (16), and suppresses the rate of emigration of these 
cells into inflammatory exudates (17). Indeed, there is now relatively convincing 
evidence that tumor-bearing animals (18-20)  and tumor-bearing humans (21, 
22) have an impaired capacity to mount inflammatory responses in general. 
Obviously, this evidence must be considered in any proposal that attempts to 
explain  the  failure  of a  Listeria  immune host to  express  its  anti-bacterial 
immunity in its primary tumor. Indeed, the finding that the host's inability to 
fully express this immunity against bacteria in a peritoneal ascites tumor was 
associated with the presence in the peritoneal cavity of only a small number of 
macrophages, most of which were heavily parasitized, strongly suggests that an 
adequate number of effector macrophages was prevented from emigrating into 
the tumor. 
The results of this paper serve to show that there is a  striking similarity 
between the ability of a tumor-bearing animal to express acquired concomitant 
anti-tumor immunity and its ability to express acquired anti-microbial immu- 
nity. Thus, while both types of immunity can be efficiently expressed systemi- 
cally, neither can be expressed in the primary tumor. It can be suggested on the 
basis of these results, therefore, that there is probably more to an explanation of GEORGE  L.  SPITALNY AND ROBERT J.  NORTH  1275 
the paradox of concomitant anti-tumor immunity than the action of serum-block- 
ing factors. According to in vitro evidence, blocking factors in the form of tumor 
antigens, antibody, or antigen-antibody complexes, suppress specific anti-tumor 
immunity  by neutralizing the antigen recognition sites of specifically sensitized, 
cytotoxic lymphocytes. The evidence presented here shows, however, that not 
only are conditions in the tumor antagonistic to the expression of specific anti- 
tumor immunity, but that they are also antagonistic to the expression of T-cell- 
mediated anti-bacterial  immunity. It seems reasonable to suggest, therefore, 
that the reason why anti-tumor immunity is not expressed against a progressive 
primary tumor is because the tumor synthesizes molecules that pharmacologi- 
cally suppress the function of host effector cells. 
Even so,  it  is  important to point out that  in  contradiction to  the results 
presented here, intratumor inoculation of Listeria has actually been employed 
to regress murine tumors (23, 24). The contradiction, however, is more apparent 
than  real,  because  it  is  only very  small tumors that  regress  after Listeria 
inoculation. In fact, afLer tumors reach a certain critical size they not only fail to 
regress after intratumor inoculation with Listeria,  but also after inoculation 
with BCG (25). It will be recalled, however, that tumor growth has been shown 
to temporarily stop after intratumor injection of Listeria. It is apparent, there- 
fore, that partial anti-tumor therapy was in fact achieved. This is perhaps not 
surprising because  during this  time the  host was  also  capable  of partially 
expressing anti-microbial immunity in the tumors. Indeed, the published evi- 
dence  strongly suggests  (26) that  the regression of tumors by intralesional 
inoculation of BCG  requires  that  an  immune response to  this  organism be 
generated and focussed in the tumor bed. Determining the nature of the mecha- 
nism  that  prevents  the  host  from fully  expressing its  anti-tumor  defenses 
against a progressive tumor is obviously important for a  rational approach to 
the immunotherapy of cancer. It is significant in this regard, therefore, that in 
those few cases in this study where intratumor inoculation resulted in complete 
regression of Meth A foot pad tumors, Listeria was also efficiently eliminated 
from the foot pad. It seems reasonable to propose, therefore, that an understand- 
ing of the reason why anti-microbial resistance is not fully expressed in an 
established progressive tumor, will also allow an understanding of the reason 
why concomitant anti-tumor immunity is not expressed in the same site. 
Summary 
Mice carrying any one of three murine tumors in their right hind foot pad 
were incapable of eliminating an inoculum of the bacterial parasite Listeria 
monocytogenes  from the progressive tumor. In contrast, they were as capable as 
control mice in efficiently eliminating the organism from their contralateral 
tumor-free foot pad, and from their lymph nodes and livers. The results serve to 
show,  therefore,  that  conditions within  an  established  tumor are  not only 
antagonistic to the expression of concomitant anti-tumor immunity, but that 
they are  also antagonistic to the expression of T-cell-mediated anti-bacterial 
immunity. The possibility was discussed that the tumor contains factors that act 
pharmacologically to  locally suppress the function of sensitized T  cells  and 
activated macrophages. 1276  SUBVERSION  OF HOST  DEFENSE  MECHANISMS  BY  MALIGNANT  TUMORS 
The excellent technical assistance  of Thomas Arsenault, Jonathan Deissler, and Deena Scapper- 
otta is gratefully acknowledged. 
Received for publication 19 January 1977. 
References 
1.  HellstrSm, K. E., and I. HellstrSm. 1969. Cellular immunity against tumor antigens. 
Adv. Cancer Res.  12:167. 
2.  Vaage,  J.  1971. Concomitant immunity  and  specific depression  of immunity by 
residual or reinjected syngeneic tumor tissue. Cancer Res. 31:1655. 
3.  Gershon, R.  K.,  R.  L.  Carter,  and K. Kondo.  1967. On concomitant immunity in 
tumor-bearing hamsters. Nature  (Lond.).  213:674. 
4.  Kearney, R.,  A.  Basten,  and D.  S.  Nelson.  1975. Cellular basis  for the immune 
response to methylcholanthrene-induced tumors in mice. Heterogeneity of effector 
cells. Int. J. Cancer.  15:438. 
5.  North,  R. J.,  and D.  P.  Kirstein.  1977. T  cell-mediated concomitant immunity to 
syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immu- 
nity to unrelated tumors and bacterial parasites. J. Exp. Med.  145:275. 
6.  Baldwin, R. W., M. J. Embleton, and R. A. Robins. 1973. Humoral factors influenc- 
ing cell-mediated immune  responses to tumor-associated antigens.  Proc.  R.  Soc. 
Med. 66:466. 
7.  HellstrSm, I., H. O. Sjogren, G. Warner, and K. E. HellstrSm. 1971. Blocking of cell- 
mediated tumor immunity by sera from patients with growing neoplasms. Int. J. 
Cancer.  7:226. 
8.  Baldwin,  R.  W.,  M.  R.  Price,  and  R.  A.  Robins.  1972. Blocking of lymphocyte- 
mediated  cytotoxicity for rat  hepatoma  cells  by tumor-specific antigen-antibody 
complexes. Nat. New Biol. 238:185. 
9.  Pierce, G. E. 1971. Enhanced growth of primary Moloney virus-induced sarcomas in 
mice. Int. J. Cancer. 8:22. 
10.  Old, L. J., D. A. Clarke, B. Benacerraf, and M. Goldsmith. 1960. The reticuloendo- 
thelial system and the neoplastic process. Ann. N.  Y. Acad. Sci. 88:264. 
11.  Hibbs, J. H., L. H. Lambert, and J. S. Remington. 1972. Possible role of macrophage 
mediated nonspeoific cytotoxicity in tumor resistance. Nat. New Biol.  235:48. 
12.  Keller,  R.  1973. Cytostatic elimination of syngeneic rat  tumor  cells  in  vitro by 
nonspecifically activated macrophages. J. Exp. Med.  138:625. 
13.  North,  R.  J.,  D.  P.  Kirstein,  and R.  L.  Tuttle.  1976. Subversion of host defense 
mechanisms by murine tumors. I. A circulating factor that suppresses macrophage- 
mediated resistance to infection. J. Exp. Med.  143:559. 
14.  North,  R.  J.,  D.  P.  Kirstein,  and R.  L.  Tuttle.  1976. Subversion of host defense 
mechanisms  by  murine  tumors.  II.  Counter-influence of concomitant  antitumor 
immunity. J. Exp. Med.  143:574. 
15.  North, R. J. 1974. Cell-mediated immunity and the response to infection. In Mecha- 
nisms of Cell-Mediated Immunity.  R.  T.  McCluskey and S.  Cohen,  editors. John 
Wiley & Sons, Inc., New York and London. 185-220. 
16.  Pike, M. C., and R. Snyderman. 1976. Depression of macrophage function by a factor 
produced by neoplasms:  a  mechanism for abrogation of immune  surveillance. J. 
Immunol.  117:1243. 
17.  Snyderman,  R.,  M.  C.  Pike,  B.  L.  Blaylock,  and  P.  Weinstein.  1976. Effects of 
neoplasms on inflammation: depression of macrophage accumulation a~r  tumor 
implantation. J. Immunol.  116:585. 
18.  Mahoney, M. J., and J. Leighton. 1962. The inflammatory response to a foreign body 
within transplantable tumors. Cancer Res.  22:334. GEORGE  L. SPITALNY  AND  ROBERT  J. NORTH  1277 
19. Bernstein,  I. D., B. Zbar,  and H. J. Rapp. 1972.  Impaired inflammatory responses in 
tumor-bearing guinea pigs.  J. Natl. Cancer Inst. 49:1641. 
20. Fauve, R. M., B. Hevin, H. Jacob,  J.  A. Gaillard,  and F. Jacob.  1974.  Antiinflarnma- 
tory effects of murine malignant cells. Proc. Natl. Acad. Sci.  U. S. A.  71:4052. 
21.  Dizon, Q. S., and C. M. Southam. 1963. Abnormal cellular response to skin abrasions 
in cancer patients. Cancer. 14:1288. 
22.  Johnson, M. W., H. I. Maibach, and S. E. Salmon. 1973. Quantitative impairment of 
primary  inflammatory responses  in  patients  with  cancer.  J.  Natl.  Cancer Inst. 
51:1075. 
23.  Youdim,  S.,  M.  Moser,  and  O.  Stutman.  1974. Nonspecific suppression  of tumor 
growth  by an immune reaction to Listeria  monocytogenes. J.  Natl.  Cancer Inst. 
52:193. 
24.  Bast, R. C., Jr., B. Zbar, G. B. Mackaness, and H. J. Rapp. 1975. Antitumor activity 
of bacterial  infection.  I.  Effect of Listeria  monocytogenes  on growth  of a  murine 
fibrosarcoma. J. Natl. Cancer Inst.  54:759. 
25.  Zbar, B., I. D. Bernstein,  G. L. Bartlett,  M.  G. Hanna, Jr.,  and H. J. Rapp.  1972. 
Immunotherapy of cancer:  regression  of intradermal  tumors  and  prevention  of 
growth of lymph node metastases after intralesional  injection of living Mycobacte- 
rium bovis.  J. Natl. Cancer Inst.  49:119. 
26.  Zbar, B., E. Ribi, M. Kelly, D. Granger, C. Evans, and H. J. Rapp. 1976. Immunolog- 
ical  approaches to  the  treatment  of human  cancer based on a  guinea pig mode. 
Cancer Immunol. Immunother. 1:127. 